Acquisitions involving innovator drugs have grown year-on-year with total deal value increasing eight-fold to almost $18 ...

Revolution Medicines has partnered Royalty Pharma for $2bn to support development and commercialisation of its RAS(ON) ...

The US FDA has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid.

Novo Nordisk has ended a partnership with telehealth company Him & Hers, after launching the collaboration less than two ...

Membrane is a winner in the Innovation, Research & Development, and Environmental categories in the 2025 Pharmaceutical ...

Navamedic has signed an agreement for the acquisition of Norwegian company dne pharma in a deal valued at Nkr225m ($22m).

The FDA's new genAI-assisted scientific review technology, named Elsa, was officially adopted by the agency on 2 June.

An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.

Harbour BioMed has entered a strategic partnership with Otsuka focusing on the development of HBM7020 for treating autoimmune ...

Nicole Verdun, a highly respected individual in the cell and gene therapy space, was placed on administrative leave this week ...

Revenue for Madrigal’s Rezdiffra, already approved in the US, is expected to skyrocket over the coming decade.